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Abstract
Introduction: CYP19A1 encodes aromatase, the enzyme responsible for the conversion of androgens to estrogens, and may
play a role in variation in outcomes among men and women with cardiovascular disease. We sought to examine genetic
variation in CYP19A1 for its potential role in sex differences in cardiovascular disease outcomes.
Methods: Caucasian individuals from two independent populations were assessed: 1) a prospective cohort of patients with
acute coronary syndromes with 3-year mortality follow-up (n=568) and 2) a nested case-control study from a randomized,
controlled trial of hypertension patients with stable coronary disease in which the primary outcome was death, nonfatal
myocardial infarction (MI) or nonfatal stroke (n=619). Six CYP19A1 SNPs were genotyped (-81371 C.T, -45965 G.C, M201T,
R264C, 80 A.G, and +32226 G.A). The sex*genotype interaction term was assessed for the primary outcome and
compared by genotype in men and women when a significant interaction term was identified.
Results: We identified a significant interaction between -81371 C.T and sex (p=0.025) in the ACS population. The variant
allele was associated with a 78% increase in mortality in men (HR 1.78, 95% confidence interval [CI] 1.08-2.94) and a
nonsignificant 42% decrease in mortality among women (HR 0.58, 95% CI 0.22-1.54). We identified a similar association in
the hypertensive CAD group, the -81371 C.T*sex interaction term was p,0.0001, with an associated 65% increase in death,
MI, or stroke (HR 1.65, 95% CI 1.00-2.73) in men and a 69% decrease (HR 0.31, 95% CI 0.16-0.6) in women.
Conclusions: Using two independent populations, this study is the first to document a significant interaction between
CYP19A1 genotype and sex on cardiovascular outcomes. These findings could illuminate potential mechanisms of sex
differences in cardiovascular disease outcomes.
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Introduction
Aromatase is the enzyme that catalyzes the conversion of
androgens to estrogens and is the primary pathway of estrogen
production in men and post-menopausal women. It is encoded for
by the CYP19A1 gene located on chromosome 15q21.1. Many
investigators have evaluated the role of CYP19A1 polymorphisms
in breast cancer, endometrial cancer, prostate cancer, bone health,
Alzheimer’s disease, obesity, and hormonal status. Recently,
CYP19A1 has also been investigated for its role in blood pressure
regulation.[1,2] Two studies have noted an association between
CYP19A1 single nucleotide polymorphisms (SNPs) and blood
pressure in women, but not in men.[1,2] However, whether
differences in blood pressure by CYP19A1 genotype translate into
sex-specific differences in outcomes has not been assessed. This
question is quite relevant given the differences in cardiometabolic
risk factors between men and women and the fact that some of
these differences may be related to sex hormones.[3,4] Further-
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15180more, uncertainty about the role of reproductive hormones in
cardiovascular health (as evidenced by divergent results from
epidemiological and clinical trials of hormone replacement
therapy) necessitates careful consideration of sexual dimorphism
when assessing the impact of hormone-related gene variants in
cardiovascular risk.
Given the postulated role of estrogens and androgens on
cardiovascular health and sex-related differences in cardiovascular
disease risk factors, we hypothesized that CYP19A1 polymorphisms
would be associated with outcomes in cardiovascular disease. We
sought to examine both the overall effect of CYP19A1 and to
explicitly test for gene*sex interactions and sex-specific differences
in these genetic variants and outcome using two independent
coronary artery disease (CAD) populations, one with acute
coronary syndromes (ACS) and one with stable CAD.
Methods
Patient Populations
The methods of the first population (The INvestigation oF
Outcomes from acute coronary syndRoMes study [INFORM]), a
prospective cohort of patients with acute coronary syndromes
(ACS) have been previously described.[5] Briefly, patients
admitted to one of two Kansas City hospitals with a confirmed
ACS were enrolled. Myocardial infarction (MI) was defined by
elevated troponin level in combination with chest pain symptoms
or electrocardiographic findings (ST-segment elevation or non-
ST-segment elevation) consistent with MI. Unstable angina was
defined by a negative troponin level and any one of the following:
new-onset angina (,2 months), prolonged angina (.20 minutes)
at rest, recent worsening angina, or angina that occurred within 2
weeks of MI.[6] Participating patients were interviewed during
their admission in order to obtain demographic characteristics.
Chart abstractions were performed in order to obtain medical
histories, detailed medication histories, laboratory histories, and
information regarding inpatient care at time of initial event.
All-cause mortality assessment was made using the Social
Security Administration Death Master File (http://www.ntis.gov/
products/ssa-dmf.asp).
The second population assessed consisted of the case-control
group of the INternational VErapamil SR/trandolapril Study
genetic substudy (INVEST-GENES), which has also been
previously described.[7,8] Patients with hypertension and stable
coronary artery disease were randomized to either a beta-blocker-
based or calcium antagonist-based treatment regimen with
additional anti-hypertensive medications added, as necessary, to
control blood pressure. The primary outcome of the study was
time to first occurrence of death, nonfatal myocardial infarction
(MI), or nonfatal stroke. The nested-case control group was
created by using the 258 subjects from the genetic subset who
experienced a primary outcome event as cases and age-, sex-, and
race-frequency-matching 781 individuals who did not experience
the primary outcome as controls.
Both INFORM and INVEST were multi-ethnic but only
Caucasian individuals were used for these analyses (568/723 for
INFORM and 619/1054 for INVEST).
INFORM was approved by the University of Missouri- Kansas
City Adult Health Sciences Institutional Review Board and
INVEST was approved by the University of Florida Institutional
Review Board-01. Written informed consent was obtained from all
participants.
Genotyping
Genomic DNA was isolated from whole blood samples (for
INFORM) or buccal cells (for INVEST) using standard methods.
Six single nucleotide polymorphisms (SNPs) with minor allele
frequencies greater than 0.04 were chosen based on prior
resequencing data and functional studies (for nonsynonymous
SNPs) and to emphasize SNPs with putative functional significance
(promoter, synonymous, and 39 untranslated region SNPs).[9] The
SNPs consisted of two located in the promoter region: -81371 C.T
(rs4774585) and -45965 G.C (rs936308); two nonsynonymous
SNPs: M201T (rs28757184) and R264C (rs700519); one synony-
mous SNP: 80 A.G (rs700518); and one SNP located in the 39
UTR: +32226 G.T (rs4646) (Figure 1).Genotypingwasconducted
using pyrosequencing (PSQ HS 96) or Taqman (ABI 7700). The
PCR primers and conditions are available upon request. PCR
Figure 1. CYP19A1 schematic with SNP locations. Exons are shown as vertical lines (noncoding in black coding in grey), introns are shown as the
horizontal space between exons. SNP positions are indicated by vertical lines below the figure.
doi:10.1371/journal.pone.0015180.g001
Table 1. Allele Frequencies in INFORM and INVEST.
SNP* INFORM INVEST
-81371 C.T 0.23 0.22
-45965 G.C 0.15 0.17
80 G.A 0.51 0.50
M201T 0.03 0.04
R264C 0.03 0.04
32266 G.T 0.27 0.27
*SNP- single nucleotide polymorphism, presented as A.B, where B indicates
minor allele.
doi:10.1371/journal.pone.0015180.t001
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master mix, 0.5 mL( 1mmol) forward and reverse primer, 10 ng
DNA, and 8 mL water. Taqman assays (C__27892984_10,
C___1664163_10, C___8794675_30, C___8234730_1, and C__
25972590_30) were carried out according to manufacturers’
instructions.
Statistical Analysis
Baseline characteristics were compared by ANOVA, student’s t-
test or chi-square tests as appropriate. Allele frequencies were
calculated by allele counting and deviations from Hardy-Weinberg
equilibrium were assessed using chi-square tests. For the
INFORM cohort, Cox proportional hazards models were
developed that included the following pre-specified covariates:
age, sex, ACS type (ST elevation MI, non ST elevation MI, or
unstable angina), coronary revascularization strategy (medical
management, percutaneous coronary intervention, or coronary
artery bypass graft), ejection fraction, history of heart failure,
hypertension, diabetes, and CYP19A1 genotype (according to an
additive model of inheritance). Given the role of aromatase in sex
hormone metabolism, genotype-by-sex interaction terms were
assessed and analyses were also conducted stratified by sex if the
interaction term was significant (primary analysis) and in the
overall population (secondary analysis). For the INVEST case-
control population, logistic regression models were developed
including age, sex, BMI, blood pressure, history of MI, heart
failure, diabetes, or stroke, smoking, ACE inhibitor use, diuretic
use, and treatment randomization group and genotype (according
to an additive model of inheritance)-by-sex interaction terms.
Haplotypes were assigned using PHASE (version 2.1).
Figure 2. Linkage disequilibrium plots for Caucasians. Panels A and B are INFORM and panels C and D are INVEST. The colored plots show D’
and the black and white plots show r
2. Blank red boxes indicate D’ of 1.0.
doi:10.1371/journal.pone.0015180.g002
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The first population (INFORM) consisted of 568 Caucasian
ACS patients who consented to participate in the genetic analyses
of this study. Genotyping was complete for 98%, 91%, 96%, 98%,
99%, and 97% for -81371 C.T, -45965 G.C, 80 A.G, M201T,
R264C, and 32266 G.T, respectively. The second population
(INVEST-GENES) consisted of 619 Caucasian hypertensive
patients with stable coronary disease. Genotyping was complete
for 87%, 96%, 97%, 98%, 96%, and 99%) for -81371 C.T,
-45965 G.C, 80 A.G, M201T, R264C, and 32266 G.T,
respectively. Allele frequencies for Caucasian INFORM and
INVEST-GENES are shown in Table 1. As expected, no genotype
frequencies differed by sex and no SNP deviated from Hardy-
Weinberg equilibrium expectations (sex-stratified or overall). The
linkage disequilibrium plots for INFORM and INVEST are
shown in Figure 2.
INFORM patients were, on average, 61612 years of age, of
whom 36% were women, and 29% presented with ST elevation
MI, 30% with non-ST elevation MI, and 41% with unstable
angina (Table 2). Consistent with previous investigations of ACS,
women were older, had higher BMI, were more likely to present
with unstable angina or non-ST elevation MI and, had a greater
prevalence of hypertension, heart failure, and diabetes than men
(Table 2).[10,11] The INVEST-GENES case-control patients
were, on average 71610 years of age, made up of 51% women,
and 33% had a history of MI, 62% had chronic stable angina, and
49% had an abnormal angiogram that qualified them for the study
(Table 2). The baseline characteristics compared by genotype and
sex are shown in File S1.
Adjusted hazard ratios for individual SNPs in the INFORM
overall population, men, and women are shown in Table 3. We
identified a significant interaction between -81371 C.T and sex
in whites (p=0.02, Table 3). In white men, the variant allele was
associated with a significant increase in mortality and in women
the variant allele was associated with a nonsignificant decreased
risk of mortality (Table 3). In the overall INFORM population
(men and women combined), -81371 was associated with a 72%
increase in mortality (HR 1.72, 95% CI 1.06-2.79) and M201T
was associated with a nearly 3-fold increase in mortality (HR 2.99,
95% CI 1.15-7.78). The Kaplan Meier event plots are shown in
File S1. Whereas the association with -81371 C.T was divergent
by sex, the association with M201T was similar in men and
women (Table 3). We did not identify any significant associations
for -45965 G.C, 80 G.A, or +3266 G.T with long-term
mortality.
Table 2. Baseline Characteristics- INFORM and INVEST-GENES.
INFORM
(n=568)
INFORM Men
(n=370)
INFORM Women
(n=198)
INVEST
(n=619)
INVEST Men
(n=314)
INVEST Women
(n=305)
Age, mean 6 SD, years 62612 61612 64613 71610 69697 3 610
BMI, mean 6 SD, kg/m2 29.465.9 29.065.5 30.166.5 28.365.1 28.564.3 28.165.9
Smoking status, number (%)
Current 185 (33) 127 (34) 58 (29) 67 (11) 42 (13) 25 (8)
Past 220 (39) 154 (42) 66 (33) 258 (42) 162 (52) 96 (31)
Never 162 (29) 88 (24) 74 (37) 294 (48) 110 (35) 184 (60)
SBP, mean 6 SD, mmHg 134625 136625 132624 149619 146618 151620
DBP, mean 6 SD, mmHg 72615 74615 69614 82611 82611 82611
ACS type, number (%)
ST elevation MI 174 (31) 128 (35) 46 (23) n/a n/a n/a
Non-ST elevation MI 182 (32) 112 (30) 70 (35) n/a n/a n/a
Unstable angina 210 (37) 130 (40) 80 (43) n/a n/a n/a
Old LBB/Unknown 2 (0.4) 0 (0) 2 (1) n/a n/a n/a
Chronic stable angina, number (%) n/a n/a n/a 291 (47) 125 (40) 166 (54)
Unstable angina .1 mo ago,
number (%)
n/a n/a n/a 104 (17) 74 (24) 30 (10)
Abnormal angiogram, number (%) n/a n/a n/a 416 (67) 252 (80) 165 (54)
Abnormal stress test, number (%) n/a n/a n/a 127 (21) 84 (27) 43 (14)
ACS treatment strategy, number (%)
Medical management 162 (29) 99 (27) 63 (32) n/a n/a n/a
PCI 379 (67) 252 (68) 127 (64) n/a n/a n/a
CABG 27 (5) 19 (5) 8 (4) n/a n/a n/a
Myocardial infarction, number (%) 183(32) 115 (31) 68 (34) 265 (43) 142 (45) 123 (40)
Hypertension, number (%) 356 (63) 208 (56) 148 (75) 619 (100) 314 (100) 305 (100)
Heart failure, number (%) 31 (5) 14 (54) 17 (129) 33 (5) 13 (4) 20 (7)
Diabetes, number (%) 137 (24) 80 (22) 57 (29) 12 (2) 5 (2) 7 (2)
Hormone replacement therapy,
number (%)
55 (10) 2 (0.45) 53 (27) 81 (13) 0 (0) 81 (27)
n/a not applicable.
doi:10.1371/journal.pone.0015180.t002
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we observed the same significant interaction between -81371
C.T and sex (p,0.0001, Table 3). In white men, the variant
allele was associated with a 65% increase in the primary
outcome (OR 1.65, 95% CI 1.00-2.73) and in women, the variant
allele was associated with a 69% reduced risk of the primary
outcome (OR 0.31, 95% CI 0.16-0.60) (Table 3). Unlike the ACS
cohort, -81371 C.T was not significantly associated with the
primary outcome in the overall population, potentially due to the
higher percentage of women in INVEST-GENES than INFORM.
The association with M201T and outcomes were not replicated in
INVEST-GENES. The case-control status by genotype is shown
in File S1.
Haplotype analysis was not consistently more informative than
the individual SNP analyses (data not shown).
Discussion
We identified a significant interaction between CYP19A1 -81371
C.T genotype and sex on mortality after an ACS. This finding
was replicated in an independent population of patients with stable
CAD and hypertension. The variant allele was associated with an
increase in outcomes among men and a decreased risk of outcomes
in women. To our knowledge, this is the first report of such an
association.
These findings markedly extend previous investigations of
CYP19A1 and cardiovascular disease. While the mechanisms of
these sex-divergent genotype effects on mortality are currently
unknown, previous work lends support for this phenomenon. For
example, using data from the Framingham Heart Study, Peter et
al found a single SNP in CYP19A1 in which the homozygous
variant genotype was associated with higher diastolic blood pressure
in women and lower pulse pressure in men.[1] Additionally,
Ramirez-Lorca et al reported an association with CYP19A1 and
blood pressure in women, but not men.[2] Therefore, our findings
are the first of our knowledge in large cardiovascular disease
populations to extend the previous sex-dependent effects of
CYP19A1 on blood pressure to adverse outcomes.
Unfortunately, we do not have access to hormone levels in these
populations. However, Peter et al have previously found SNPs in
CYP19A1 (including rs700518 investigated in this study) to be
associated with estradiol, testosterone, and the estradiol to
testosterone ratio in men, but not in women.[12] The minor
allele rs700518 (A) carriers had higher estradiol, lower testosterone
levels, and higher estradiol to testosterone ratios than the major
(G) allele homozygotes. Therefore, taken together with previous
epidemiological data, our findings in which -81371 C.T male
variant carriers had increased mortality might suggest that -81371
T (or a linked SNP) is associated with lower testosterone levels and
lower testosterone to estradiol ratio.{Laughlin, 2008 #19}{Peter,
2008 #18}
Our findings support several potential hypotheses as to the
underlying mechanisms responsible for the observed sex differ-
ences in CYP19A1 associations. First, sex-biased gene expression is
increasingly being identified across many organisms’ genomes.[13]
In fact, up to 57% of genes in Drosophila melanogaster have been
found to have sex-biased expression, many of which are expressed
in reproductive tissues.[14,15] If CYP19A1 is susceptible to
differences in expression between sexes, this could allow for the
same variant to have different effects because of differences in
trans-regulation of gene expression. A second explanation for the
sex-differences we observed is different sex-dependent relation-
ships between androgens and cardiovascular disease or insulin
resistance. Hyperandrogenic conditions in women such as
polycystic ovary disease have been associated with insulin
resistance and an increased risk of cardiovascular death or
MI.[16,17]. In contrast, hypoandrogenism in men has been
associated with insulin resistance and increased mortality.[17,18]
Therefore, our findings of a polymorphism in CYP19A1 being
associated with excess risk in men, while being protective in
women, may be the result of differences in effects of sex hormones
in men and women. Finally, our sex-divergent findings may result
from gene-by-environment interactions. Men and women differed
in their age at presentation, body mass indices, the frequency of
comorbid conditions including hypertension, diabetes, and heart
failure, and in the type of ACS with which they presented, all
factors which were adjusted for in our analyses with the sex-by-
genotype interaction still persisting. Therefore, aromatase poly-
morphisms may interact with any of these variables in their
influence on prognosis (although we did not detect any such
Table 3. Adjusted Hazard Ratios/Odds Ratios and 95%
Confidence Intervals by Individual SNPs in Whites.
SNP
All
whites
Genotype*sex
interaction
whites
White
men
White
women
INFORM
-81371
C.T
1.72
(1.06-2.79)
p=0.03*
0.02* 1.78
(1.08-2.94)
p=0.025*
0.58
(0.22-1.54)
p=0.28
-45965
G.C
0.95
(0.55-1.63)
p=0.84
0.56
80
G.A
1.16
(0.79-1.70)
p=0.46
n/a
M201T 2.99
(1.15-7.78)
p=0.025*
0.91
R264C 0.31
(0.04-2.33)
p=0.26
0.99
32226
G.T
0.97
(0.63-1.48)
p=0.87
0.50
INVEST-GENES
-81371
C.T
0.88
(0.60-1.27)
p=0.48
7.9610
25* 1.65
(1.00-2.73)
p=0.05
0.31
(0.16-0.60)
p=0.0006*
-45965
G.C
1.10
(0.74-1.64)
p=0.62
0.018* 0.66
(0.36-1.20)
p=0.17
1.83
(1.00-3.32)
p=0.048*
80
G.A
0.99
(0.73-1.34)
p=0.94
0.33
M201T 1.15
(0.57-2.34)
p=0.70
0.98
R264C 1.79
(0.83-3.90)
p=0.14
0.44
32226
G.T
1.00
(0.72-1.40)
p=0.99
0.62
*indicates p,0.05.
n/a indicates not able to be calculated due to small numbers.
doi:10.1371/journal.pone.0015180.t003
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differences between men and women (e.g. the hormonal
environment) which could result in different effects of the same
genotype in men as compared with women.
Limitations
The vast majority of the women in these studies were likely post-
menopausal given that the minimum age for enrollment in
INVEST was 50 (mean 7269) and the mean age in INFORM was
62613 years. Using an age cut-off of 55 years and hormone
replacement therapy use, only 127 women in INFORM and 130
women in INVEST were less than 55 or on hormone replacement
therapy. Therefore, a limitation of our study is that these small
numbers prevented us from being able to conduct any meaningful
analyses using hormonal status instead of just sex. Further, our
findings are likely not translatable to younger, premenopausal
women.
Another limitation of our study is that we do not have access to
hormone levels in these populations which would be very valuable
for assessing genotype associations. Last, the CYP19A1 gene is
very large and we only looked at common SNPs with putative
function located across the gene. We did not fully tag the gene and
hence, the genomic coverage is actually quite low. Therefore, we
cannot rule out other associations with unmeasured SNPs nor can
we determine the causative functional SNPs based on the observed
associations. Last, there is the potential for type I error.
Conclusions
We have identified a striking association between CYP19A1
genotype and outcomes in a group of post-ACS patients which was
divergent in men and women. We replicated these findings in an
independent population of hypertensive patients with stable
coronary disease. In men, the CYP19A1 -81371 C.T variant
was associated with an increased risk of adverse outcomes, whereas
in women, the variant was associated with a reduced risk for
adverse outcomes. These findings could have broad implications
for understanding sex differences in cardiovascular disease, the
treatment of CVD, the therapeutic uses of aromatase inhibitors,
and risk assessment for CVD prognosis.
Supporting Information
File S1 Includes tables of baseline characteristics by genotype
and sex for INFORM and INVEST, table of case/control status
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